Key facts
- This page summarizes Robert Iannone's Form 4 filing for Jazz Pharmaceuticals plc (JAZZ).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 07 Jun 2023, 19:16.
Robert Iannone - 05 Jun 2023 Form 4 Insider Report for Jazz Pharmaceuticals plc (JAZZ)
- Reporting relationship
- EVP, Global Head of Research a
- Issuer ticker
- JAZZ
- Reported as of
- 05 Jun 2023
- Net transaction value
- -$170,076
- SEC form
- 4
- Accepted by SEC
- 07 Jun 2023, 19:16:49 UTC
- Prior SEC filing
- 04 May 2023
- Next SEC filing
- 15 Jun 2023
- Source filing
- View source filing
- Reporting owner signature
- By: Adam Guttman, as attorney in fact For: Robert Iannone
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Robert Iannone filed Form 4 for Jazz Pharmaceuticals plc (JAZZ) on 07 Jun 2023.
Change
- Previous filing in this sequence was filed on 04 May 2023.
- Current net transaction value: -$170,076.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
JAZZ
transaction
Ordinary Shares
Disposed to Issuer
- Transaction value
- $170,076
- Shares
- -1,311
- Change %
- -2.8%
- Price
- $129.73
- Shares after
- 45,315
- Date
- 05 Jun 2023
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units.
Footnote F2
Includes 137 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on May 31, 2023.